Cheaper cancer drug copy tested in melanoma trial – but study halted early

NCT ID NCT06587451

Terminated Disease control Sponsor: Sandoz Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a biosimilar (JPB898) against the original immunotherapy Opdivo, both combined with Yervoy, in 52 adults with advanced melanoma that could not be surgically removed. The goal was to see if the biosimilar works just as well. However, the trial was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab biosimilar (JPB898) plus ipilimumab (Yervoy)
What this could lead to: If successful, this could show that a more affordable biosimilar works as well as the original drug for advanced melanoma.
What could go wrong: The trial was terminated early with only 52 participants, so results are limited. Biosimilars may not always match the original drug's effectiveness or safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Locations

Sandoz Investigational Site

Santiago, Chile
Sandoz Investigational Site

Athens, Greece
Sandoz Investigational Site

Thessaloniki, Greece
Sandoz Investigational Site

Pisa, Italy
Sandoz Investigational Site

Vilnius, Lithuania
Sandoz Investigational Site

Kuala Lumpur, Malaysia
Sandoz Investigational Site

Pulau Pinang, Malaysia
Sandoz Investigational Site

Putrajaya, Malaysia
Sandoz Investigational Site

Bacolod, Philippines
Sandoz Investigational Site

Warsaw, Poland
Sandoz Investigational Site

Lisbon, Portugal
Sandoz Investigational Site

Daejeon, South Korea
Sandoz Investigational Site

Málaga, Spain
Sandoz Investigational Site

Oviedo, Spain
Sandoz Investigational Site

Santander, Spain
Sandoz Investigational Site

Santiago de Compostela, Spain
Sandoz Investigational Site 1

Santiago, Chile
Sandoz Investigational Site 1

Busan, South Korea
Sandoz Investigational Site 2

Tbilisi, Georgia
Sandoz Investigational Site 2

Seoul, South Korea
Sandoz Investigational Site 2

Madrid, Spain
Sandoz Investigational Site 2

Valencia, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.